Sign In
Buy ETON
$27.61
+0.210 (+0.766%)
At Close: Jun 03, 2026
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates
06:36pm, Thursday, 06'th Nov 2025
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.13. This compares to earnings of $0.02 per share a year ago.
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
04:05pm, Thursday, 06'th Nov 2025
Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growth Q3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GA
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
04:30pm, Thursday, 23'rd Oct 2025
DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
06:50am, Wednesday, 20'th Aug 2025
DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript
03:27pm, Friday, 08'th Aug 2025
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R.
Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options
05:02am, Friday, 08'th Aug 2025
Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to
Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates
07:10pm, Thursday, 07'th Aug 2025
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.12 per share a year ago.
Eton (ETON) Q2 Revenue Jumps 108%
06:06pm, Thursday, 07'th Aug 2025
Eton Pharmaceuticals (ETON), a biopharmaceutical company focused on rare diseases, posted earnings for Q2 2025 on August 7, 2025. The main highlight was a strong revenue increase from both core and re
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 07'th Aug 2025
Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-
Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:01am, Thursday, 31'st Jul 2025
Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
07:00am, Monday, 28'th Jul 2025
DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharma Near Term Catalysts Vanish
09:33am, Tuesday, 15'th Jul 2025
Important near-term catalysts for ETON have been eliminated due to insider stock sales and a disappointing partial FDA approval for their new drug, Khindivi. Insider sales by the CEO and CBO after Q1
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
06:50am, Tuesday, 08'th Jul 2025
- NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
06:50am, Friday, 27'th Jun 2025
DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
05:26pm, Friday, 06'th Jun 2025
Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline fueling future expansion. Despite a 400% share price surge, ETON remains attr
